Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients
Status:
Recruiting
Trial end date:
2023-02-02
Target enrollment:
Participant gender:
Summary
This is a single-group treatment, phase IV, open label study to assess the mobilization
efficacy and safety of plerixafor in combination with G- CSF in male and female participants
from 18 to 75 years of age with multiple myeloma for autologous transplantation. Study
Duration-Screening-up to 30-day. Intervention and CD34+cells apheresis up-to 8 day. A follow
up for 30 days (+7 days) post last dose of plerixafor, or the initiation of ablative
chemotherapy, or the first dose of G-CSF administration in rescue procedure, whichever occurs
earlier. Study duration up to 75 days. For treatment phase visit frequency daily.